Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Cytochrome P-450 2C9 substrates: Other than warfarin, no formal interaction studies between
capecitabine and other CYP2C9 substrates have been conducted. Care should be exercised when
capecitabine is co-administered with 2C9 substrates (e.g., phenytoin). See also interaction with
coumarin-derivative anticoagulants below, and section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Coumarin-derivative anticoagulants: altered coagulation parameters and/or bleeding have been
reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such
as warfarin and phenprocoumon. These reactions occurred within several days and up to several
months after initiating capecitabine therapy and, in a few cases, within one month after stopping
capecitabine. In a clinical pharmacokinetic interaction study, after a single 20 mg dose of warfarin,
capecitabine treatment increased the AUC of S-warfarin by 57% with a 91% increase in INR value.
Since metabolism of R-warfarin was not affected, these results indicate that capecitabine down-
regulates isozyme 2C9, but has no effect on isozymes 1A2 and 3A4. Patients taking coumarin-
derivative anticoagulants concomitantly with capecitabine should be monitored regularly for
alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted
accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-05-02T14:45:00Z · SHA-256 632b962270222a1b1c9626101f7ef2fdc0c5500039de7f68bd6fd6e7e22b7b52 · Passage f7452e2b078b6ee5dc45ef4e375246458e3f25c847078c541bd34cf7c6b48abd · Zeichen 1080–2047 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.